.

Revance Therapeutics reported $77.23M in Current Liabilities for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Aerie Pharmaceuticals AERI:US $ 119.66M 4.37M
ALKERMES ALKS:US $ 438.52M 23.84M
Bristol Myers Squibb BMY:US $ 20915M 1906M
Cara Therapeutics CARA:US $ 21.17M 2.87M
Coherus Biosciences CHRS:US $ 140.75M 12.99M
Eli Lilly And LLY:US $ 15620.6M 2234.6M
Endo International Ordinary Shares ENDP:US $ 1181.67M 194.47M
Horizon Pharma HZNP:US $ 791.06M 34.12M
JAZZ PHA JAZZ:US $ 705.44M 31.97M
Neurocrine Biosciences NBIX:US $ 285.7M 32.2M
Pacira Pharmaceuticals PCRX:US $ 133.18M 171.89M
Procter & Gamble PG:US $ 33081M 1320M
Revance Therapeutics RVNC:US $ 77.23M 6.16M
Supernus Pharmaceuticals SUPN:US $ 735.54M 450.98M
Teva Pharmaceutical Industries TEVA:US $ 10996M 617M